1. Home
  2. IOVA vs TRS Comparison

IOVA vs TRS Comparison

Compare IOVA & TRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.42

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo TriMas Corporation

TRS

TriMas Corporation

HOLD

Current Price

$36.67

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOVA
TRS
Founded
2007
1986
Country
United States
United States
Employees
975
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Specialties
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2008
2004

Fundamental Metrics

Financial Performance
Metric
IOVA
TRS
Price
$3.42
$36.67
Analyst Decision
Buy
Strong Buy
Analyst Count
10
2
Target Price
$9.00
$41.50
AVG Volume (30 Days)
13.7M
382.1K
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
0.44%
EPS Growth
14.84
400.00
EPS
N/A
2.95
Revenue
N/A
$645,720,000.00
Revenue This Year
$47.74
$5.42
Revenue Next Year
$40.31
$4.27
P/E Ratio
N/A
$12.25
Revenue Growth
N/A
N/A
52 Week Low
$1.64
$20.95
52 Week High
$5.63
$42.00

Technical Indicators

Market Signals
Indicator
IOVA
TRS
Relative Strength Index (RSI) 44.48 48.80
Support Level $2.05 $35.41
Resistance Level $4.33 $37.20
Average True Range (ATR) 0.30 1.07
MACD -0.02 -0.17
Stochastic Oscillator 22.44 35.44

Price Performance

Historical Comparison
IOVA
TRS

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

About TRS TriMas Corporation

TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.

Share on Social Networks: